ECOR ECOR
Company Profile ↓Company Overview
ECOR (ECOR) is a publicly traded company listed on with a market capitalization of $52.27M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 58.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $32.03M (+27.2% YoY); net profit $-13.97M.
- Trailing 12 Months Year-on-year growth — revenue +27.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.32% |
| 1 Year: | 27.20% |
Stock Price Performance
| 1 Year: | -9.93% |
| 6 Months: | +7.58% |
| 3 Months: | -6.58% |
| 1 Month: | -17.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 117.00K | 177.00K | 283.00K | 234.00K | 81.19K | 393.23K | 150.97K | 368.00K | 409.60K | 622.74K | 682.99K | 733.77K | 752.96K | 1.08M | 1.20M | 1.27M | 1.49M | 1.90M | 2.16M | 1.98M | 2.78M | 3.55M | 4.51M | 5.44M | 6.14M | 6.55M | 6.72M | 7.38M | 8.69M | 9.58M |
| Gross Profit | - | 137.81K | 154.92K | - | 32.24K | 152.74K | 53.91K | - | 251.81K | 368.30K | 329.05K | 435.66K | 479.97K | 733.34K | 840.00K | 895.00K | 1.13M | 1.54M | 1.80M | 1.72M | 2.32M | 2.97M | 3.85M | 4.55M | 5.30M | 5.49M | 5.71M | 6.44M | 7.47M | 8.36M |
| Operating Income | -4.74M | -7.43M | -5.99M | -7.49M | -9.10M | -16.22M | -13.55M | -15.68M | -14.21M | -12.38M | -10.89M | -8.01M | -5.92M | -4.49M | -5.38M | -5.20M | -3.98M | -5.58M | -5.82M | -5.56M | -6.20M | -4.99M | -4.13M | -3.85M | -2.59M | -2.65M | -3.82M | -3.51M | -2.88M | -5.32M |
| Net Income | - | -11.57M | -12.36M | - | -9.50M | -17.78M | -19.37M | -15.34M | -13.86M | -12.10M | -10.69M | -7.96M | -4.74M | -4.49M | -5.38M | -2.89M | -3.99M | -5.58M | -5.34M | -5.45M | -5.87M | -4.90M | -4.03M | -3.51M | -2.65M | -2.50M | -3.85M | -3.67M | -3.40M | -5.27M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.20 | -1.20 | -1.20 | -1.24 | -1.03 | -0.68 | -0.53 | -0.38 | -0.31 | -0.47 | -0.44 | -0.40 | -0.59 |
| R&D Expense | - | 2.77M | 1.88M | - | 2.31M | 4.37M | 2.33M | - | 3.46M | 2.51M | 2.27M | 1.52M | 1.03M | 629.00K | 499.00K | 825.00K | 470.00K | 934.00K | 1.34M | 1.62M | 1.81M | 1.16M | 1.25M | 399.00K | 635.00K | 521.00K | 642.00K | 511.00K | 662.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 811.46K | 992.95K | 2.39M | 3.50M | 5.45M | 8.59M | 16.03M | 25.18M | 32.03M |
| Gross Profit | 292.93K | 414.21K | 1.23M | 1.76M | 4.07M | 6.98M | 13.23M | 21.40M | 27.79M |
| Operating Income | -25.64M | -54.55M | -46.09M | -24.75M | -20.04M | -22.87M | -19.27M | -12.16M | -13.15M |
| Net Income | -35.79M | -55.82M | -45.15M | -23.51M | -17.22M | -22.16M | -18.83M | -11.89M | -13.97M |
| Diluted EPS | - | - | - | - | -4.36 | -4.69 | -3.42 | -1.59 | -1.65 |
| R&D Expense | 7.83M | 12.47M | 9.90M | 4.20M | 2.54M | 5.52M | 5.32M | 2.36M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 39.23M | 73.50M | 35.46M | 31.52M | - | 24.76M | 16.10M | 20.47M | 18.67M |
| Current Assets | - | - | - | - | - | - | 21.17M | 14.29M | 16.30M | 15.67M |
| Cash & Equivalents | 416.34K | 13.22M | 7.60M | 13.56M | 4.24M | - | 17.71M | 10.33M | 3.70M | 7.04M |
| Inventory | - | - | - | - | - | - | 1.98M | 2.16M | 1.68M | 1.63M |
| Receivables | - | - | - | - | - | - | 401.00K | 717.00K | 1.37M | 1.03M |
| Total Liabilities | - | 6.43M | 7.32M | 10.56M | 7.87M | - | 7.67M | 8.66M | 12.93M | 20.38M |
| Current Liabilities | - | 6.12M | 7.07M | 9.14M | 5.89M | - | 7.04M | 8.12M | 9.15M | 11.35M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 6.61M |
| Total Debt | - | - | - | - | - | - | 699.00K | 626.00K | 4.14M | 9.40M |
| Total Equity | - | -90.07M | 65.55M | 24.26M | 23.01M | - | 17.09M | 7.44M | 7.54M | -1.71M |
| Shares Outstanding | - | - | - | - | - | - | 4.74M | 6.00M | 6.65M | 8.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.33M | -47.11M | -45.07M | -20.05M | - | -16.64M | -14.67M | -6.95M | -8.19M |
| Investing Cash Flow | -24.12M | -36.83M | 50.97M | -7.96M | - | 0 | -206.00K | -8.52M | 3.88M |
| Financing Cash Flow | 62.49M | 78.33M | 160.84K | 18.90M | - | 0 | 7.49M | 8.44M | 7.63M |
| Capital Expenditure | -152.53K | -278.92K | -69.67K | - | - | - | -206.00K | - | -66.00K |
| Free Cash Flow | -25.48M | -47.39M | -45.14M | - | - | -16.64M | -14.87M | -6.95M | -8.25M |
| Net Change in Cash | - | - | - | - | - | -16.64M | -7.39M | -7.03M | 3.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 36.1% | 41.7% | 51.6% | 50.3% | 74.6% | 81.2% | 82.5% | 85.0% | 86.8% |
| Operating Margin % | -3,160.3% | -5,494.1% | -1,928.2% | -707.9% | -367.7% | -266.2% | -120.2% | -48.3% | -41.1% |
| Net Margin % | -4,410.9% | -5,621.7% | -1,888.8% | -672.5% | -315.9% | -257.9% | -117.5% | -47.2% | -43.6% |
| ROE % | 39.7% | -85.2% | -186.1% | -102.2% | - | -129.7% | -253.1% | -157.6% | 817.2% |
| ROCE % | -77.4% | -82.1% | -175.1% | -96.6% | - | -129.2% | -241.5% | -107.4% | -179.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ECOR
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences: Need…
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, …
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publicat…
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today
RALEIGH, NC / ACCESS Newswire / June 23, 2026 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference begins today, bringing together small and micro-cap public companies and investors for a full day of company presentations, foll…
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026
RALEIGH, NC / ACCESS Newswire / June 18, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Summer Investment Conference on June 23-24, 2026, bringing together small and micro-cap public companies and investors fo…
ECOR — Frequently Asked Questions
What is the current share price of ECOR?
As of 2026-08-05 17:25 PDT, ECOR trades at $6.53 on NASDAQ/NYSE. Its 52-week range is $4.31 to $10.35.
What is the market capitalisation of ECOR?
ECOR has a market capitalisation of $52.27M on NASDAQ/NYSE.
What is the P/E ratio of ECOR?
ECOR trades at a trailing price-to-earnings (P/E) ratio of -3.96. Its price-to-book (P/B) ratio is -30.59.
Is ECOR a good stock to buy?
This page provides a data-driven analysis of ECOR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.